Impact of initial antibiotic choice on mortality from pneumococcal pneumonia

European Respiratory Journal

Volumn 27, Issue 5, 2006, Pages 1010-1019

  Aspa, J ^a   Rajas, O ^a   de Castro, F Rodriguez ^b   Huertas, M C ^c   Borderias L ^d   Cabello, F J ^e   Tabara J ^f   Hernandez Flix S ^g   Martinez Sanchis, A ^h   Torres, A ⁱ  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

^e Hospital de la Serrania   (Spain)

^f Hospital Cristal Pinor   (Spain)

^g HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^h HOSPITAL MARINA BAIXA   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

Author keywords

Antimicrobial resistance; Mortality; Pneumococcal pneumonia; Risk factors; Streptococcus pneumoniae

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLARITHROMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CHRONIC LUNG DISEASE; CLINICAL OBSERVATION; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG CHOICE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; SCORING SYSTEM; SPAIN; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33751039945     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00126004     Document Type: Article

References (42)

1. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
2. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumomae. Am J Respir Crit Care Med 1999; 159: 1835-1842.
3. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-528.
4. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med 2004; 32: 625-631.
5. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-237.
6. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-2580.
7. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123: 1503-1511.
8. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-2572.
9. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-1426.
10. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030-1035.
11. Waterer GW, Somes GW, Wunderin RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-1842.
12. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107: 34S-43S.
13. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389-395.
14. Burgess DS, Lewis JS 2nd. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22: 872-878.
15. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000; 46: 973-980.
16. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-444.
17. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004; 38: 787-798.
18. Mortensen EM, Coley CM, Singer DE, ek al. Causes of death for patients with community-acquired Pneumonia: results from the pneumonia patient outcomes Research Team cohort study. Arch Intern Med 2002; 162: 1059-1064.
19. Fenoll A, Martin Bourgon C, Munoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
20. Fenoll A, Jado I, Vicioso D, Perez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998; 36: 3447-3454.
21. National Committee for Clinical Laboratory Standards (2002) Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. Document M1OO-S12. Wayne, National Committee for Clinical Laboratory Standards, 2002.
22. Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to Antimicrobial Vermont, Therapy. Antimicrobial Therapy, Inc, 2000.
23. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
24. Parmar M, Machin D. Survival Analysis. A practical Approach. New York, John Wiley and Sons, 1995.
25. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-1754.
26. Menendez R, Torres A, Rodríguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-1790.
27. Alfageme I, Aspa J, Bello S, et al. [Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).]. Arch Bronconeumol 2005; 41: 272-289.
28. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
29. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 1405-1433.
30. Ortega M, Marco F, Soriano A, Gómez J, Almela M, Mensa J. In vitro antagonism between β-lactam and macrolide in Streptococcus pneumoniae: how important is the antibiotic order? Int J Antimicrob Agents 2004; 24: 178-180.
31. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330: 456-460.
32. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005; 165: 1992-2000.
33. Menendez R, Torres A, Zalacain R, et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172: 757-762.
34. Aujesky D, Fine MJ. Does guideline adherence for empiric antibiotic therapy reduce mortality in community-acquired pneumonia? Am J Respir Crit Care Med 2005; 172: 655-656.
35. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-847.
36. Dowell SF. The best treatment for pneumonia: new clues, but no definitive answers. Arch Intern Med 1999; 159: 2511-2512.
37. Macfarlane J. Severe pneumonia and a second antibiotic. Lancet 2002; 359: 1170-1172.
38. File TM Jr, Mandell LA. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis 2003; 36: 396-398.
39. Waterer GW. Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire? Chest 2003; 123: 1328-1329.
40. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-2084.
41. Powers JH, Cooper CK. Evaluating combination therapy in community-acquired pneumonia. Chest 2004; 125: 353.
42. File TM Jr, Segreti J, Dunbar L, et al. A multicenter randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972.